Optical coherence tomography in multiple sclerosis

Elliot Frohman, Fiona Costello, Robert Zivadinov, Olaf Stuve, Amy Conger, Heather Winslow, Anand Trip, Teresa Frohman, Laura Balcer

Research output: Contribution to journalReview articlepeer-review

144 Scopus citations


We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.

Original languageEnglish (US)
Pages (from-to)853-863
Number of pages11
JournalLancet Neurology
Issue number10
StatePublished - Oct 2006

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Optical coherence tomography in multiple sclerosis'. Together they form a unique fingerprint.

Cite this